Sorrento Therapeutics, Inc. (SRNE)

Oncology Corporate Profile

Stock Performance

4.1000
0.0000

HQ Location

6042 Cornerstone Ct. West, Suite B
San Diego, CA 92121

Company Description

Sorrento is an oncology company developing new treatments for cancer and its associated pain. Sorrento's most advanced asset Cynviloq, the next-generation paclitaxel, commenced its registrational trial on March 31, 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opioid TRPV1 agonist currently in a Phase 1/2 study at the National Institutes of Health to treat terminal cancer patients suffering from intractable pain.

Website: http://sorrentotherapeutics.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
cynviloqmonoclonal antibodyBreast CancerIII
cynviloqmonoclonal antibodyNon Small Cell Lung Cancer (NSCLC)III
cynviloqmonoclonal antibodyBladder cancerII
cynviloqmonoclonal antibodyOvarian cancerII
cynviloqmonoclonal antibodyPancreatic CancerII

View additional information on product candidates here »

Source


http://sorrentotherapeutics.com

Recent News Headlines

Sorrento and Wildcat Announce Resolution

3/20/2017 12:00 pm

[PR Newswire] - SAN DIEGO, March 20, 2017 /PRNewswire/ -- Sorrento Therapeutics, Inc. (SRNE) (the "Company" or "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, and Wildcat Capital Management LLC ("Wildcat"), whose clients currently are major holders of the outstanding common stock of Sorrento, today jointly announced that they have reached a mutual understanding and resolution with respect to Wildcat's claims seeking inspection of documents related to the Company's private placement agreements announced by the Company in April 2016 ("Inspection Demand Action") and Wildcat's derivative action against the Company and certain members of its Board of Directors filed in May 2016 ("Derivative Action").

Sorrento and Wildcat Announce Resolution

3/20/2017 12:00 pm

[CNW Group] - Sorrento and Wildcat Announce Resolution

Sorrento Therapeutics to Present at 29th Annual ROTH Conference

3/9/2017 10:00 pm

[PR Newswire] - "Sorrento"), an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases announced today that it will participate in the 29th Annual ROTH Conference taking place at The Ritz-Carlton, Laguna Niguel in Dana Point, CA. Sorrento will hold investor meetings and Kevin Herde, Executive Vice President, and Chief Financial Officer, will present at 1:30 p.m. Pacific Time on March 13, 2017. Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases.

The Life Sciences Report Examines the Inclusion of Sorrento Therapeutics on Streetwise Reports' 2017 Small-Cap Biotech Watchlist

1/23/2017 02:00 pm

[Marketwired] - The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. ...

Sorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™

1/9/2017 02:00 pm

[PR Newswire] - SAN DIEGO, Jan. 9, 2017 /PRNewswire/ -- SCILEX Pharmaceuticals Inc. ("SCILEX"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") today announced that its pivotal study for its lead investigational product, ZTlido™ (lidocaine patch 1.8%), has met a primary endpoint establishing comparative pharmacokinetics and a secondary endpoint of bioequivalence as compared to the reference product in Europe, Versatis® (lidocaine medicated plaster 5%). This study (EU pivotal study) was performed similarly to the previously reported US pivotal study which established comparative pharmacokinetics and bioequivalence between ZTlido™ and Lidoderm® (lidocaine patch 5%). The full data is planned to be filed with the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom as part of a hybrid Marketing Authorization Application (MAA) in mid-2017.

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

12/21/2016 01:03 pm

[Business Wire] - Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and discovering new ways to use the body’s immune system to fight cancer.

Sorrento Subsidiary, SCILEX Pharmaceuticals Announces Key Endpoints Met in Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™

12/5/2016 12:00 pm

[PR Newswire] - SAN DIEGO, Dec. 5, 2016 /PRNewswire/ -- SCILEX Pharmaceuticals Inc. ("SCILEX"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") today announced that its pivotal study for lead investigational product, ZTlido™ (lidocaine patch 1.8%), has met a primary endpoint establishing comparative pharmacokinetics and a secondary endpoint of bioequivalence for ZTlido as compared to the reference product, Lidoderm® (lidocaine patch 5.0%). The full data will be resubmitted to the U.S. Food and Drug Administration (FDA) as part of the 505(b)(2) new drug application (NDA) in mid-2017. ZTlido is a next-generation lidocaine patch currently in development for the treatment of post-herpetic neuralgia ("PHN"), a severe neuropathic pain condition.

Sorrento's TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for Treatment of Hematological Malignancies

12/1/2016 03:02 pm

[at noodls] - - Novel Anti-CD38 CAR-T and Anti-CD123 CAR-T Programs Utilizing Sorrento's Fully Human Antibodies Demonstrated Strong Anti-Tumor Activity in Preclinical Models of Multiple Myeloma and Acute Myeloid Leukemia, ...

Sorrento's TNK Therapeutics Provides Progress Update for its Anti-CD38 and CD123 CAR-T Programs for Treatment of Hematological Malignancies

12/1/2016 12:02 pm

[PR Newswire] - "Sorrento"), has provided an update on its lead chimeric antigen receptor (CAR) expressing T cells (CAR-T) programs for the treatment of hematological malignancies. Adoptive immunotherapy utilizing CAR-T cells represents a promising new paradigm in the treatment of cancer. Sorrento intends to present these findings at upcoming clinical conferences and in scientific publications. The anti-CD38 CAR-T program is in development for the treatment of multiple myeloma. The membrane glycoprotein CD38 is highly expressed on multiple myeloma cells, and thus, represents a valuable therapeutic target against myeloma.